Page last updated: 2024-09-05

tesaglitazar and Cardiac Failure

tesaglitazar has been researched along with Cardiac Failure in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Area-Gomez, E; Chin, A; Civelek, M; Drosatos, K; Goldberg, IJ; Kalliora, C; Kyriazis, ID; Lieu, MJ; Madesh, M; Mizushima, W; Oka, SI; Pol, CJ; Sadoshima, J; Scerbo, D; Schulze, PC; Tian, Y; Yue, Y1

Other Studies

1 other study(ies) available for tesaglitazar and Cardiac Failure

ArticleYear
Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
    JCI insight, 2019, 08-08, Volume: 5

    Topics: Alkanesulfonates; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisomes; Phenylpropionates; PPAR alpha; PPAR gamma; Receptors, Leptin; Sirtuin 1; Transcription Factors; Transcriptome

2019